SCHEMBL24070682

SCHEMBL24070682

Cc1cn(-c2cc(NC(=O)c3ccc(C)c(CNc4cnc5[nH]ccc5c4)c3)cc(C(F)(F)F)c2)cn1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 1/20 0.69
▸ MAP3K20 Q9NYL2 1/20 0.69
▸ ABL1 P00519 10/20 0.64
▸ BCR P11274 10/20 0.64
▸ HCK P08631 2/20 0.64
▸ EGFR P00533 1/20 0.64
▸ LCK P06239 1/20 0.64
▸ FYN P06241 1/20 0.64
▸ YES1 P07947 1/20 0.64
▸ LYN P07948 1/20 0.64
▸ SRC P12931 1/20 0.64
▸ BRAF P15056 1/20 0.64
▸ PDGFRA P16234 1/20 0.64
▸ FRK P42685 1/20 0.64
▸ MAP3K7 O43318 1/20 0.61
▸ MAP4K2 Q12851 1/20 0.61
▸ NR2E1 Q9Y466 3/20 0.57
▸ LDLR P01130 1/20 0.56
▸ KIT P10721 1/20 0.56
▸ PCSK9 Q8NBP7 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30447296 1.00 MAPK14 (0.69) MAPK14MAP3K20ABL1BCRHCK
SCHEMBL30339882 0.90 MAPK14 (0.66) MAPK14MAP3K20ABL1BCRHCK
SCHEMBL24070473 0.90 MAPK14 (0.66) MAPK14MAP3K20ABL1BCRHCK
SCHEMBL24070143 0.86 DDR1 (0.65) MAPK14MAP3K20ABL1BCRSRC
SCHEMBL30211927 0.86 DDR1 (0.65) MAPK14MAP3K20ABL1BCRSRC
SCHEMBL3424818 0.85 MAPK14 (0.62) MAPK14MAP3K20ABL1BCRHCK
SCHEMBL4789491 0.85 ABL1 (0.69) MAPK14MAP3K20ABL1BCRHCK
SCHEMBL25339043 0.84 ABL1 (0.60) MAPK14MAP3K20ABL1BCRHCK
SCHEMBL30211930 0.84 ABL1 (0.60) MAPK14MAP3K20ABL1BCRHCK
SCHEMBL24070155 0.83 ABL1 (0.59) MAPK14MAP3K20ABL1BCRHCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230227447-A1 BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2023-07-20 — — US claimed
CN-115697485-A Benzylamine derivatives as DDR inhibitors 奇斯药制品公司 2023-02-03 — — CN claimed
US-20230227447-A1 BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2023-07-20 — — US disclosed
US-20230227447-A1 BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2023-07-20 — — US disclosed
US-20230227447-A1 BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2023-07-20 — — US disclosed
WO-2021239643-A1 BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2021-12-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230227447-A1 BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS DDR2, DDR1, DDRGK1 MAPK14 2850/4885MAP3K20 459/4885ABL1 399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback